Radboud Repository

Radboud University Nijmegen

PDF hosted at the Radboud Repository of the Radboud University Nijmegen

The following full text is a publisher's version.

For additional information about this publication click this link.
http://hdl.handle.net/2066/118254

Design and Analysis of Effects of Triplet Repeat Oligonucleotides in Cell Models for Myotonic Dystrophy

Anchel González-Barriga[1,2], Susan AM Mulders[1,2], Jeroen van de Giessen[2], Jeroen D Hooijer[1,3], Suzanne Bijl[2], Ingeborg DG van Kessel[1], Josee van Beers[1], Judith CT van Deutekom[2], Jack AM Fransen[1], Bé Wieringa[1] and Derick G Wansink[1]

Myotonic dystrophy type 1 (DM1) is caused by DM protein kinase (*DMPK*) transcripts containing an expanded (CUG)n repeat. Antisense oligonucleotide (AON)-mediated suppression of these mutant RNAs is considered a promising therapeutic strategy for this severe disorder. Earlier, we identified a 2′-O-methyl (2′-OMe) phosphorothioate (PT)–modified (CAG)7 oligo (PS58), which selectively silences mutant *DMPK* transcripts through recognition of the abnormally long (CUG)n tract. We present here a comprehensive collection of triplet repeat AONs and found that oligo length and nucleotide chemistry are important determinants for activity. For significant reduction of expanded *DMPK* mRNAs, a minimal length of five triplets was required. 2′-O,4′-C-ethylene-bridged nucleic acid (ENA)–modified AONs appeared not effective, probably due to lack of nuclear internalization. Selectivity for products from the expanded *DMPK* allele in patient myoblasts, an important requirement to minimize unwanted side effects, appeared also dependent on AON chemistry. In particular, RNase-H–dependent (CAG)n AONs did not show (CUG)n length specificity. We provide evidence that degradation of long *DMPK* transcripts induced by PS58-type AONs is an RNase-H independent process, does not involve oligo-intrinsic RNase activity nor does it interfere with splicing of *DMPK* transcripts. Our collection of triplet repeat AONs forms an important resource for further development of a safe therapy for DM1 and other unstable microsatellite diseases.

Introduction

Myotonic dystrophy type 1 (DM1) is an autosomal dominant, trinucleotide repeat expansion disease and the most common form of adult onset muscular dystrophy.[1–3] The multisystemic symptoms are highly variable and involve different tissues and organs, including skeletal muscle, heart, brain, eyes, reproductive systems, and the gastrointestinal tract. No cure to slow or stop the disease process is currently available.

The genetic basis of DM1 is an unstable (CTG)n expansion in the 3′-untranslated region of the DM protein kinase (*DMPK*) gene. Length of the (CTG)n segment is correlated with age of onset and severity of disease.[1] In the healthy population, the CTG repeat is polymorphic in length, with a triplet number that ranges from 5 to 37 (mostly below 15),[4] whereas disease alleles may contain between 50 and >2,000 triplets.[1]

The DM1 pathogenic mechanism involves an RNA gain-of-function. Repeat-containing transcripts from the expanded allele accumulate in cell nuclei and alter the function of RNA-binding proteins, whose association with disease has been most intensively studied for muscleblind (MBNL) and CUG-binding protein 1 (CUGBP1).[2] In adult DM1 tissue, the resulting imbalance in availability of these antagonistic splicing regulators causes misregulation of events in which embryonic patterns of splicing occur. For example, myotonia and insulin resistance, two key features of DM1, may be caused by altered splicing of muscle chloride channel and insulin receptor transcripts, respectively.[2] Also effects on microRNA processing and function have been reported.[5]

Results obtained with DM1 mouse models that inducibly express (CUG)n RNA show that features of RNA toxicity are reversible,[6] strongly suggesting that reducing the level of expanded *DMPK* transcripts will be beneficial to patients. In the past decade, different antisense strategies have been developed with the intention to eliminate expanded *DMPK* transcripts *via* either antisense RNA expression, ribozyme activity, oligo-mediated RNase-H activity or RNA interference (RNAi) technology.[7] Reduction of *DMPK* transcript levels was achieved by several of these methods, but selectivity between toxic and normal-sized transcripts was generally low.

To be functional and safe for therapeutic use in DM1 patients, an antisense approach should ideally silence transcripts from the expanded allele only and leave normal-sized *DMPK* transcripts or unrelated transcripts containing (CUG)n segments intact. Since length of the (CUG)n repeat is the only consistent polymorphic difference between mutant and normal *DMPK* (pre)mRNAs, the repeat tract itself forms an attractive therapeutic target. Besides, despite the fact that normal and mutant *DMPK* transcripts are both made in the nucleus, (CUG)n length selectivity may be enhanced by directing active compounds to this compartment where mutant transcripts accumulate after synthesis.

Earlier, we published on the identification and characterization of PS58, an antisense oligonucleotide (AON) complementary to the (CUG)n repeat.[8] PS58 is a (CAG)7 fully

2′-*O*-methyl (2′-OMe) phosphorothioate (PT)-modified AON, which silences expanded (CUG)n transcripts in DM1 cell and animal models. Other *in vivo* AON studies directed at the expansion mutation made use of a (CAG)n morpholino to interfere with the (CUG)n repeat–MBNL interaction[9] or LNA (locked nucleic acid)/MOE (2′-*O*-methoxyethyl)-PT–type (CAG)n gapmers to recruit RNase-H activity for degradation of (CUG)n-containing transcripts.[10] François *et al.* engineered a hU7-(CAG)15-small nuclear RNA which preferentially reduced pathogenic *DMPK* mRNA in DM1 cells, *via* a yet unknown mechanism.[11]

Here, we report on specific properties that (CUG)n-directed AONs require for effective knockdown of expanded *DMPK* RNA. Triplet repeat AONs with different chemistries and lengths were tested in an unbiased screen for silencing capacity in a transgenic DM1 cell culture model expressing human *DMPK (CUG)500* transcripts. AON length and nucleotide chemistry appeared to be major parameters for therapeutic efficacy. A selection of effective AONs was tested in DM1 patient myoblasts. Findings of this study are important for transition towards *in vivo* studies with AONs and ultimately for development of a specific AON-mediated therapy for DM1. As a first step in support of this transition, we report on effects on *in vitro* complement activation by some of these AONs.

Results

AONs complementary to *DMPK*'s (CUG)n repeat

A series of triplet repeat AONs that differed in length, chemistry, and nucleotide composition was designed and analyzed for their ability to silence expanded *DMPK* transcripts in cultured cells (see AON description in **Figure 1a**). AONs were tested *via* transfection in the DM500 myoblast–myotube cell model.[8] The human *DMPK* (*hDMPK*) transgene in this model is under near-normal myogenic transcriptional control and produces *hDMPK* transcripts bearing a (CUG)500 repeat at levels comparable to that of endogenous mouse *Dmpk* (*mDmpk*) transcripts. It should be noted that *mDmpk* transcripts contain a CCG(CUG)$_2$(CAG)$_2$CUG sequence instead of the generally believed to be uninterrupted (CUG)n segment found in *hDMPK* transcripts. Monitoring AON-silencing effects was done by northern blotting to follow steady-state levels of full-length transgenic *hDMPK* transcripts and possible stable breakdown products. Analysis of endogenous *mDmpk* transcripts was used as a control. Reverse transcription-quantitative PCR (RT-qPCR) was included for quantitative assessment of expression of defined transcript segments.

DNA-based (CAG)n AONs

DNA-type oligonucleotides are known to allow specific RNase-H–mediated cleavage of RNA in a DNA–RNA heteroduplex.[12] For these AONs, several chemical modifications have been developed that improve their metabolic stability, while maintaining hybridization affinity to target RNA and ability to recruit RNase H.[13] We tested three DNA-type (CAG)7 AONs in DM500 myotubes: PS56, a pure DNA AON; PS142, a PT-modified DNA AON; and PS260, a PT-modified chimeric AON, so called gapmer, comprised of 2′-OMe wings on the 5′ and 3′ sides of a DNA gap. DNA AON PS56

did not show silencing activity (**Figure 1a**), probably because it was quickly degraded inside cells (**Supplementary Figure S1**). In contrast, PS142 and PS260–both stabilized against nuclease breakdown–were able to silence expanded *hDMPK* mRNA for ~50 and 80%, respectively (**Figure 1a,b**). Endogenous *mDmpk* mRNA was left intact. A concentration–response analysis yielded an IC$_{50}$ (half maximal inhibitory concentration) of 0.3 ± 0.4 µmol/l for DNA/PT oligo PS142, which is about 1,000-fold lower than that of 2′-OMe/PT lead compound PS58 (**Figure 1c**, **Supplementary Figure S2** and ref. 8).

Oligo length and base variations of 2′-OMe AONs

To investigate length as a potential parameter in the performance of PS58-type oligos, we tested a series of fully 2′-OMe–modified (CAG)n AONs consisting of 4–13 triplets in the DM500 myotube culture system. All, except PS251 (CAG)4, effectively and selectively silenced (CUG)500 transcripts (>80% efficiency) (**Figure 1a,b**). A (CAG)7 2′-OMe sense oligo or 2′-OMe oligos directed against target sequences in the *hDMPK* transcript outside the repeat did not have a silencing effect (data not shown).[8] The lack of activity of the (CAG)4 AON is best explained by assuming that a minimum oligo length is necessary for effective hybridization to the (CUG)n target needed for AON activity.

We wondered whether the nature of the nucleotide residue at the 5′ or 3′ end of the AON might be crucial for silencing and tested a repeat-shifted version, 2′-OMe–modified (AGC)7 (PS259). PS259 treatment resulted in a significant reduction of 85% of (CUG)500 transcripts without silencing *mDmpk* mRNA (**Figure 1a**).

Finally, a 2′-OMe–modified (CIG)7 AON was tested. The inosine residues should enable this AON, PS261, to hybridize to (CUG)n, (CAG)n, (CCG)n repeats and any combination of these triplets. Similar to PS58, PS261 induced 85% reduction of expanded mRNA (**Figure 1a**). Notably, endogenous *mDmpk* mRNA was also significantly reduced, albeit with only ~35% efficiency. This effect may be best explained by binding of (CIG)7 to the CCG(CUG)$_2$(CAG)$_2$CUG sequence in *mDmpk* mRNA. Besides, three low-affinity–binding sites were identified that could have a cooperative, additive effect (11–13 nucleotides match; not present in *hDMPK* transcripts).

Silencing of expanded *hDMPK* transcripts by triplet repeat 2′-OMe AONs in DM500 myotubes was independently confirmed by RT-qPCR analysis (**Figure 1d**). The lower silencing efficiency measured by RT-qPCR (60–90 versus 85–95% detected by northern blotting) is attributed to technical differences in sensitivity intrinsic to the methods.

Morpholino phosphorodiamidate (CAG)n AONs

Morpholino phosphorodiamidate oligos are uncharged AONs widely used as blocking oligos for selective inhibition of gene expression.[14] A (CAG)8 morpholino (PS304) was tested for its ability to silence expanded *hDMPK* RNA in DM500 myotubes. The morpholino was coupled to an octaguanidine dendrimer (so called Vivo-Porter) to facilitate cellular uptake. PS304 treatment caused a 70% reduction of (CUG)500 transcripts, leaving *mDmpk* mRNA intact (**Figure 1a**).

Triplet Repeat Oligos for Myotonic Dystrophy
González-Barriga et al.

npg

3

Figure 1 Collection of triplet repeat AONs tested for their ability to silence expanded *hDMPK* mRNA in DM500 myotubes. (**a**) Summary of silencing efficiency. Endogenous *mDmpk* RNA was included as a negative control, since it lacks a pure (CUG)n repeat. AONs are grouped according to their main chemical modification: [a]DNA (capital); RNA (capital, underlined); PT, phosphorothioate linkage (*); 2′-OMe, 2′-*O*-methyl sugar modification (capital, underlined, bold); ENA, 2′-*O*,4′-*C*-ethylene-bridged nucleic acid (capital, italics); PMO, morpholino phosphorodiamidate (lower case); [b]Cy3-labeled; [c]Coupled to octaguanidine dendrimer. The means of at least three independent experiments for each AON are shown. Dashed line indicates 100% levels (mock samples). (**b**) Representative northern blots with RNA isolated from AON-treated DM500 myotubes probed with a *hDMPK* and a *Gapdh* probe. Results of treatment with three AONs (200 nmol/l) or mock treatment is shown. (**c**) Concentration–response curves of PS58 and PS142. DM500 myotubes were treated with a concentration series of 0.01–500 nmol/l AON (see also **Supplementary Figure S2**). (**d**) RT-qPCR analysis of *hDMPK* RNA levels in DM500 myotubes after treatment with a selection of 2′-OMe AONs (200 nmol/l, $n \geq 3$). PCR amplicons were located in exon 15, either 5′ or 3′ to the (CUG)n tract. *$P < 0.05$; **$P < 0.01$; ***$P < 0.001$. AON, antisense oligonucleotide; *Gapdh*, glyceraldehyde 3-phosphate dehydrogenase; *hDMPK*, human DM protein kinase; *mDmpk*, mouse *Dmpk*; RT-qPCR, reverse transcription-quantitative PCR.

npg

Triplet Repeat Oligos for Myotonic Dystrophy
González-Barriga et al.

4

2′-O,4′-C-ethylene-bridged nucleic acid-modified (CAG)n AONs

The bicyclic modification in 2′-O,4′-C-ethylene-bridged nucleic acid (ENA) confers strong nuclease resistance and high-binding affinity to complementary single-stranded RNA (average ΔT_m (Δmelting temperature)/modification = 5.5 versus 1.3 °C for 2′-OMe)[15] (**Supplementary Figure S1**). We tested two fully ENA-modified AONs consisting of three and four CAG triplets, and three ENA/2′-OMe gapmers of 5, 7, and 10 CAGs (PS139-135, **Figure 1a**). Only treatment with PS136 resulted in a small, yet significant reduction (30%) of *hDMPK* RNA expression.

The discrepancy in efficacy between ENA- and 2′-OMe–modified AONs may be caused by differences in subcellular targeting. To verify this possibility, we followed cellular uptake and routing of two fluorescently labeled AONs with these modifications. For these analyses, we switched to the use of DM500 myoblasts, which display a rather flat morphology, rendering them more suitable for live cell imaging of AON localization than myotubes. Forty minutes after transfection, fluorescent PS58 oligo was present in the cell nucleus and signal intensity further increased up to 60 minutes (**Supplementary Figure S3**). This behavior was independent of the type of fluorophore used and fluorophore coupling did not affect PS58 silencing activity (data not shown). In contrast, labeled PS138, as a representative of the ENA AON collection, was concentrated in vesicle-like structures and rarely present in the nucleus itself. This pattern remained unchanged up to 48 hours after transfection (data not shown). We conclude that lower silencing efficiency of ENA-modified (CAG)n AONs observed in this study is due to their inability to reach muscle cell nuclei, where most expanded (CUG)n transcripts reside.

Triplet repeat siRNAs

Krol *et al.*[16] reported that (CXG)n triplet repeat hairpins in mRNAs are substrates for Dicer and produce short repeat RNAs that in turn may act as short-interfering RNAs (siRNAs) against complementary repeats. We wanted to investigate whether in our cell model expanded *hDMPK* mRNAs could be silenced by introducing synthetic (CAG)n/(CUG)n siRNAs. Two different RNA duplexes were transfected in DM500 myotubes, PI-01 ((CAG)7/(GCU)7) and PI-02 ((GCA)7/(CUG)7) (**Supplementary Table S1**). An unrelated siRNA and PS58 were included as controls. RT-qPCR analysis demonstrated that none of the repeat siRNAs silenced *hDMPK* mRNA expression (**Figure 2**). From our AON stability assay, we conclude that it is unlikely that the inability to reduce expanded *hDMPK* transcripts is due to rapid intracellular degradation of the chemically unprotected siRNAs (**Supplementary Figure S1**).

Mouse transcripts containing a small (CUG)n segment

Transcripts that contain a (CUG)n segment, other than encoded by the *hDMPK* transgene, may also serve as targets for (CAG)n AONs in DM500 cells. Genes carrying a (CTG)n segment are rare, but at least nine transcripts in the mouse transcriptome contain a repeat of more than six triplets.[8] We investigated whether 2′-OMe/PT AONs of variable length and sequence ((CAG)5, (CAG)7, (CAG)10, and (CIG)7) acted on a subset of these transcripts expressed in DM500 myotubes.


Figure 2 RT-qPCR analysis of *hDMPK (CUG)500* RNA levels in DM500 myotubes after treatment with siRNAs (50 nmol/l) targeting the (CUG)n repeat (*n* = 6). PS58 (50 nmol/l) was used as a control. Sequences of PI-01 ((CAG)7/(GCU)7 duplex), PI-02 ((GCA)7/(CUG)7 duplex), and control siRNA are listed in **Supplementary Table S1**. **P < 0.01. *hDMPK*, human DM protein kinase; RT-qPCR, reverse transcription-quantitative PCR; siRNA, short-interfering RNA.

We analyzed transcript levels by RT-qPCR based on amplicons next to the repeat tracts (**Figure 3**; primer locations are depicted in more detail in **Supplementary Figure S4**). *Ptbp1 (CUG)6*, *Txlnb (CUG)9*, and *Mapkap1 (CUG)26*–the longest (CUG)n tract in the mouse transcriptome–showed no significant changes in expression after AON treatment (**Figure 3**). Note that due to the location of the (CUG)9 tract in the very 5′ end of the *Txlnb* gene, no suitable 5′ amplicon could be designed to measure *Txlnb* transcripts.

We also wanted to analyze RNA expression *via* amplification across the (CUG)n triplet repeat. Semi-quantitative RT-PCR for *Ptbp1* and *Txlnb* transcripts confirmed the RT-qPCR findings and showed no significant change in expression (**Supplementary Figure S5a,b**). Remarkably, quantification across the *Mapkap1 (CUG)26* repeat did record significant silencing after AON treatment, especially by PS146 (CAG)10 (**Supplementary Figure S5c**). This effect was not seen, however, when segments flanking the (CUG)26 tract were amplified in the same assay. Also northern blotting, visualizing two types of *Mapkap1* transcripts as a result of alternative polyadenylation[17] (**Supplementary Figure S4**), revealed only a minor reduction in RNA expression, whereas western blotting revealed no significant changes in Mapkap1 protein expression (**Supplementary Figure S5d,e**). We therefore decided that PCR-based quantification should not rely on amplification across a medium-sized (CUG)n tract.

Given these observations, we wanted to exclude the possibility that traces of AONs that might still be present in purified RNA samples would interfere with RT-PCR analysis. Using a hybridization–ligation method, we determined that free AON concentration in our RNA preparations was <0.2 nmol/l. To rule out interference of (CAG)n AONs with RT or PCR amplification, untreated DM500 RNA samples were spiked with 0.1–10 nmol/l PS147, PS58 or PS146 and correspondingly used in RT-PCR analysis. Presence of AONs during RT-PCR

Figure 3 Expression of three mouse transcripts, carrying a small (CUG)n repeat, after transfecting DM500 myotubes with a selection of AONs. (**a**) *Ptbp1 (CUG)6*, (**b**) *Txlnb (CUG)9*, and (**c**) *Mapkap1 (CUG)26*. RNA levels were analyzed by RT-qPCR amplifying segments flanking the triplet repeat (*n* = 3). Schemes illustrate exon–exon junctions, locations of PCR primers, and amplicons. Dashed lines indicate 100% levels (mock samples). AON, antisense oligonucletide; RT-qPCR, reverse transcription-quantitative PCR.

Figure 4 Analysis of expression levels of three mouse transcripts, containing a (CAG)n repeat, in DM500 myotubes after transfection with a selection of AONs. (**a**) *Sec24b (CAG)15*, (**b**) *Hcn1* carrying a (CAG)7 and a (CAG)20 repeat located close together (see **Supplementary Figure S4**), and (**c**) *Nr3c1 (CAG)17*. Expression was analyzed by RT-qPCR amplifying segments flanking the triplet repeat (*n* = 3). Schemes illustrate exon–exon junctions, locations of PCR primers, and amplicons. Dashed lines indicate 100% levels (mock samples). AON, antisense oligonucletide; RT-qPCR, reverse transcription-quantitative PCR.

amplification did not have an effect on *Mapkap1 (CUG)26* levels nor on quantification of *hDMPK (CUG)500* RNA (**Supplementary Figure S6**). In sum, we conclude that transcripts containing small (CUG)n tracts were largely unaffected by the (CAG)n and (CIG)n repeat oligos tested.

Mouse transcripts carrying a small (CAG)n segment
To examine the possibility that oligo-mediated *hDMPK* RNA breakdown would generate short (CUG)n RNAs that in turn might act as siRNAs on complementary (CAG)n transcripts (compare, ref. 16), we measured levels of mouse transcripts with a small (CAG)n segment: *Sec24b (CAG)15*, *Hcn1 (CAG)7+(CAG)20*, and *Nr3c1 (CAG)17*. After treatment with PS147, PS58, PS146, and PS261; no significant change in expression of any of these transcripts was detectable by

RT-qPCR analysis (**Figure 4**) ruling out an indirect effect of (CAG)n AONs on transcripts bearing a (CAG)n segment in the transcriptome.

**(CUG)n length selectivity in DM1 patient myoblasts**
A safe, antisense strategy for DM1 should differentiate between expanded and normal-sized *hDMPK* transcripts. To test this requirement, we used two DM1 myoblast cultures: one expressing *hDMPK* transcripts with 21 (normal) and 200 (mutant) triplets (abbreviated 21/200) and another with 5 and 1,400 CUG triplets (abbreviated 5/1,400).[18] Activities of three 2′-OMe AONs, PS147, PS58, and PS146, were examined in these cultures, with use of northern blotting to discriminate between normal and mutant *hDMPK* RNA. The three pure 2′-OMe/PT AONs behaved equally (**Figure 5a**): levels of *(CUG)1400* and *(CUG)200* transcripts were strongly decreased (65–95%). *(CUG)21* transcripts appeared less susceptible to breakdown (45–55%) and as expected, *(CUG)5 hDMPK* mRNA was left intact. Silencing efficacy significantly correlated with the number of CUG triplets in the transcripts (**Figure 5b**).

Western blot analysis showed that silencing of *hDMPK* transcripts by PS146 (CAG)10 resulted in around 50% loss of DMPK protein after 72 hours in 21/200 myoblasts (**Figure 6**). No effect of PS147 (CAG)5 or PS58 (CAG)7 treatment was observed at this time point.

Human transcripts containing a small (CUG)n segment
Also in the human transcriptome (CUG)n tracts are relatively rare.[8,19] Effects of a subset of 2′-OMe/PT AONs on transcripts bearing a (CUG)n repeat expressed in 5/1,400 myoblasts were examined for two transcripts: *BPGM (CUG)8* and *MAP3K4 (CUG)10* by RT-qPCR. No reduction of *BPGM* transcripts was detected after treatment with PS147 and PS146, whereas only a small effect was seen with PS58 (25% reduction) (**Figure 7a**). Similar effects for *BPGM (CUG)8* were detected in 21/200 myoblast cultures (data not shown).

Total *MAP3K4* mRNA levels were not affected by 2′-OMe AON treatment (**Figure 7b**). A conspicuous observation was made with regard to an effect on *MAP3K4* pre-mRNA processing. Analysis of the fate of alternative exon 17,[20] which

Figure 6 Analysis of DMPK protein expression after AON treatment. Human myoblasts (21/200) expressing *hDMPK (CUG)21* and *(CUG)200* transcripts were treated with a selection of (CAG)n AONs. After 72 hours, protein lysates were made and DMPK protein (arrow head) levels were analyzed by western blotting ($n = 3$). Tubulin protein was used as a loading control. Lysate from Dmpk knockout myoblasts served as reference (right two lanes). *$P < 0.05$; **$P < 0.01$. AON, antisense oligonucleotide; *hDMPK*, human DM protein kinase.

Figure 5 (CUG)n length selectivity in DM1 myoblasts. (a) Human myoblasts expressing either *hDMPK (CUG)21* and *(CUG)200* transcripts (21/200) or *hDMPK (CUG)5* and *(CUG)1400* transcripts (5/1400) were treated with a selection of CAG AONs. Northern blot analysis indicated that expanded *hDMPK* transcripts ("Exp", arrow heads) were efficiently silenced by all AONs. (CUG)21 transcripts ("Normal", double arrow heads) were moderately silenced. Only RNase-H recruiting PS260 substantially degraded (CUG)5 transcripts ("Normal", double arrow head). One representative blot of three independent experiments is shown for each cell culture. Quantification of signals is summarized in the graphs at the bottom. *$P < 0.05$; **$P < 0.01$; ***$P < 0.001$. **(b)** A significant correlation was demonstrated between the number of CTG triplets and silencing activity of PS147, PS58, and PS146 ($P < 0.05$, Pearson's correlation, $r = -0.98$), but not PS260. AON, antisense oligonucleotide; *GAPDH*, glyceraldehyde 3-phosphate dehydrogenase; *hDMPK*, human DM protein kinase.

contains the short (CUG)10 repeat that might serve as target, revealed that PS146 (CAG)10 was able to enhance exon 17 skipping (**Supplementary Figure S7**). Effects on alternative splicing by shorter (CAG)n oligos were only minor.


Figure 7 Analysis of expression of two transcripts, each containing a small (CUG)n repeat, in DM1 patient myoblasts (5/1400) after transfection with a selection of AONs. RNA levels of **(a)** *BPGM (CUG)8* and **(b)** *MAP3K4 (CUG)10* were measured by RT-qPCR ($n = 3$). Schemes illustrate exon–exon junctions and locations of PCR primers and amplicons. Dashed lines indicate 100% levels (mock samples). *$P < 0.05$; **$P < 0.01$. AON, antisense oligonucleotide; RT-qPCR, reverse transcription-quantitative PCR.

Investigating potential mechanisms of expanded *hDMPK* transcript silencing

We wondered whether exon skipping could also be the underlying or initiating mechanism of PS58-induced silencing

Figure 8 Human *DMPK (CUG)500* RNA expression in DM500 myoblasts after transfection with PS58 or scrambled-PS58. Expression of four different transcript segments (little black bars) was analyzed by RT-qPCR ($n = 3$): two in the 5′ end of the transcript and two flanking the triplet repeat in the 3′ end of the transcript. Scheme illustrates exon composition (numbered boxes) of *hDMPK* transcript, arrowhead indicates reported cryptic splicing site 3′ to the triplet repeat.[22] Dashed lines indicate 100% levels (mock samples). No significant differences in response to the oligos were observed between the four segments. ***$P < 0.001$. *hDMPK*, human DM protein kinase; RT-qPCR, reverse transcription-quantitative PCR.

of expanded *hDMPK* transcripts. *hDMPK* pre-mRNAs are subject to extensive alternative splicing and events involving final exon 15, in which the (CUG)n tract is located, have been reported.[21,22] For analysis of fate of different *hDMPK* RNA segments in presence of AONs, we used a transcript scanning RT-qPCR approach for amplicons along the expanded *hDMPK* transcript in DM500 myotubes. Amplicons were designed in the 5′ end of the gene (exon 1–exon 2, exon 4–exon 5) and on either side of the (CUG)n tract in exon 15 (**Figure 8**). No significant differences were found in signal strength for any of these *hDMPK* segments (70–85% reduction for all segments across the transcript, compared with mock-treated samples). This finding indicates that PS58-induced skipping of the (CUG)n tract during *hDMPK* pre-mRNA splicing is unlikely to be mechanistically involved.

Test tube incubation of radioactively labeled, *in vitro*-transcribed (CUG)90 RNA with a concentration series of PS58 (CAG)7 caused a mobility shift illustrating direct oligo–RNA association (**Supplementary Figure S8**). Similar shifts were seen after incubation of different (CAG)n and (CUG)n AONs with (CUG)90 or (CAG)90 RNAs (**Supplementary Figure S8**). To exclude that triplet repeat 2′-OMe AONs had an intrinsic RNase activity, similar to ribozymes or DNAzymes,[23] (CUG)n RNA was incubated with a series of different AONs in the presence of various concentrations of Mg^{2+}, Mn^{2+} or Zn^{2+} (**Supplementary Figure S8**; data not shown). No (CUG)n breakdown products could be detected, indicating that under the conditions tested, none of these AONs displayed RNase-like activity when complexed to (CUG)n RNA.

Using the same (CUG)90 RNA template, we could confirm that PS58, a fully modified 2′-OMe AON, was unable to induce RNase-H–mediated degradation of expanded (CUG)n transcripts *in vitro* (**Supplementary Figure S8**). As positive controls, we used DNA-type AON PS142 and gapmer PS260, both of which were able to recruit RNase-H to cleave

(CUG)90 RNA. Activity of gapmer PS260 was also examined in human myoblasts, but with an apparent lack of specificity (**Figures 5** and **6**). More than 60% of both expanded and normal-sized *hDMPK* transcripts were degraded. Similar lack of specificity was observed for *BPGM (CUG)8* and *MAP3K4 (CUG)10* RNAs, for which a 40% reduction in steady-state copy number was observed (**Figure 7**). Since the *MAP3K4* exon 17+ variant and the exon 17− variant (which lacks the AON target site) were equally reduced by PS260, we conclude that RNase-H–dependent degradation must have occurred in the nucleus, before exon 17 splicing (**Supplementary Figure S7**).

Complement activation by triplet repeat AONs

All triplet repeat oligos were well tolerated by cells in culture and essentially no toxic effects on growth or behavior were observed (data not shown). A well-known toxic side effect of AONs *in vivo*, especially PT-modified versions, is activation of the complement pathway.[24] As a prelude to later preclinical studies in animals and humans, we tested a selection of our PT-modified AONs with different chemistries and sequences for their ability to activate complement in plasma *in vitro*: full 2′-OMe (PS58, PS146, PS147, PS261), chimeric 2′-OMe/DNA (PS260), and pure DNA (PS142). A first generation oligonucleotide known to activate the complement pathway was included as a positive control.[25] Formation of complement split products C3a (marker for the classical and alternative pathway) and Bb (marker for the alternative complement pathway) was measured in plasma from cynomolgus monkeys and humans after addition of AONs (**Supplementary Figure S9**). In particular, PS261 (CIG)7, and to a lesser extent PS146, PS147, and PS260, caused a significant dose-dependent increase in the concentration of Bb in cynomolgus plasma. Only PS261 and PS260 activated C3a formation in human plasma. Other AONs showed no significant or minor effects.

Discussion

This study demonstrates that a range of triplet repeat AONs is capable of silencing expanded *hDMPK* transcripts. The long (CUG)n target that characterizes toxic *hDMPK* transcripts is a special RNA sequence in the sense that it can form a stem-loop structure that folds almost like an antiparallel double-stranded helix, despite the periodic U•U mismatches.[26] We conclude that the thermodynamically stable hairpin structure, known to sequester members of the MBNL protein family, does not hamper accessibility of antisense repeat AONs, when in the cellular context. The (CUG)n repeat, whose length differs between normal-short and mutant-expanded *hDMPK* transcripts, is therefore an attractive therapeutic target.

Chemical modifications of the sugar phosphate backbone of AONs serve to confer resistance against nucleases to extend cellular half-life.[13] The silencing activity of modified AONs PS142 and PS260 versus the inability of pure DNA AON PS56 to induce breakdown clearly illustrates the relationship between stability and efficacy. Oligo chemistry may also determine nucleocytoplasmic distribution of AONs. As target transcripts in DM1 are concentrated in the nucleus, an AON must be capable to enter this compartment to

become useful. Microscopic evidence is provided that ENA-modified AONs remain in vesicular structures and only inefficiently reach the nucleus, rendering them a poor choice for repeat-directed antisense DM1 strategies. We have no simple explanation for this finding, as similarly modified 2′-OMe RNA/ENA chimeras have shown activity in the nucleus during exon skipping for Duchenne muscular dystrophy.[27] Effects of nucleotide sequence on subcellular oligo localization cannot be excluded at this point. Also the type of cell model and transfection method used may have an effect.

Not all types of AONs were equally efficient and specific, but as we compared only triplet repeat oligos here, some conspicuous observations are worth mentioning. First, as an explanation for the failure of (CUG)n/(CAG)n triplet repeat siRNAs to induce an RNAi response, we assume that a combination of chemistry and oligo sequence must be responsible. The poor performance of the two duplexes tested can be the result of unfavorable subcellular distribution of siRNAs, although the RNAi machinery is known to be active in the nucleus.[28] Alternatively, the (CUG)n RNA hairpin may be insufficiently accessible to certain components of the RNAi pathway in our myogenic cell model. Very recently, a comparable triplet repeat siRNA was successfully tested *in vivo* in skeletal muscle in a mouse model for DM1. *(CUG)220* expanded RNA and also *Txlnb (CUG)9* transcripts were reduced, but not *Mapkap1 (CUG)25* RNA.[29]

Second, oligo PS261 (CIG)7 was initially considered a promising new lead compound, because of its predicted ability to bind to (CUG)n as well as (CAG)n transcripts, with potential for treatment of DM1 and polyQ diseases like Huntington's disease and several spinocerebellar ataxias. From the complement activation assay we learned, however, that this AON activated the complement cascade, rendering it a less favorable candidate for further development. Virtually none of the other AONs showed major adverse effects *in vitro*, with the best performing oligo being PS58. Screening for toxicity profiles in animals *in vivo* will be a logical next step.

Third, RNase-H recruiting AON PS260 appeared to have prominent silencing capacity, but also suffered of lack of target specificity. Further characteristics of these DNA-type AONs will be discussed below in the context of mechanistic considerations.

The main focus of our study had to do with AONs based on 2′-OMe/PT chemistry. For these AONs, we demonstrated that oligo length may provide a means to introduce selectivity between expanded transcripts from a mutated *hDMPK* allele and RNA containing a normal, short (CUG)n tract. The shortest variant in our series of 4–13 CAG triplets was unable to knockdown expanded transcripts in DM500 myotubes. The hybridization strength of the four CAG triplet AON may have been insufficient for a stable interaction with a (CUG)n segment in the living cell, even though the theoretical T_m for this interaction is around 39 °C.

AONs longer than four triplets efficiently silenced transgenic *(CUG)500* transcripts. Significant (CUG)n repeat length-dependent activity in patient cells was displayed by (CAG)5, (CAG)7, and (CAG)10 2′-OMe/PT AONs. Between them they showed no significant difference in activity towards normal-sized *hDMPK* transcripts: *(CUG)5* transcripts, expressed

by ~40% of the Caucasian population,[4] were left intact and *(CUG)21* transcripts were ~50% reduced by all three AONs. In contrast, differential effects were observed at the DMPK protein level, which might indicate a correlation with translation efficiency of remaining *hDMPK* transcripts. It should be noted that we cannot predict at the moment whether partial reduction of normal-sized transcripts will have any adverse consequences. We know that *Dmpk* knockout mice have relatively mild phenotypes,[30] hence a low level of remaining Dmpk protein might be sufficient to protect functional and structural integrity of cells in which it is expressed. Another still unresolved issue is the minimum efficacy needed for a beneficial effect. Partial suppression of toxic (CUG)n RNA may already be of clinical relevance in DM1 patients.

Expression of genes with a small (CTG)n repeat in myogenic cells was essentially unchanged upon treatment with 2′-OMe/PT AONs, except for *MAP3K4*. PS146 (CAG)10 enhanced skipping of *MAP3K4* exon 17 in which the (CUG)10 repeat is located. This (CUG)10 repeat is unusual as it is located in an alternative exon, where it might function as an exon-splicing enhancer.[31] To what extent exon 17+ and exon 17− transcript variants contribute to protein production is unknown. More importantly, it is unclear whether a shift in MAP3K4 isoform ratio would have a biological effect. Nothing is known about functional differentiation generated by inclusion of the 50 amino acid stretch encoded by in-frame exon 17 (including 10 alanines encoded by the repeat tract). The minor shift in *MAP3K4* variant ratio induced by smaller (CAG)n AONs is essentially within the normal variation observed in mock samples. Note that since splicing is a nuclear process, we can conclude that PS146 (CAG)10 must have been active inside the nucleus.

It is difficult to reconcile all observations regarding *Mapkap1 (CUG)26* transcripts. First, as also seen with *MAP3K4* transcripts, oligo length is an important parameter for AON activity and side effects seem to intensify with increased oligo length. Second, we provide ample evidence that our oligos did not interfere with RT-PCR quantification. Third, we propose that special care should be taken with RNA quantification based on amplicons covering a triplet repeat of >10 units. These amplicons will never meet requirements for RT-qPCR analysis, but they may also be useless in semiquantitative RT-PCR. For that reason, we generally used segments outside the repeat region for PCR quantification. Similar warnings regarding RT-PCR and use of AONs have been issued by others.[32] Given the location of the (CTG)26 repeat in between two alternative polyadenylation sites of the *Mapkap1* gene,[17] we cannot exclude length-dependent AON effects on splicing, transcription termination or polyadenylation. Clearly, more work is needed to be able to unequivocally interpret these data.

What do we know about the molecular mechanism underlying silencing activity of *hDMPK* transcripts by triplet repeat AONs examined here? Although the goal of this study was not to identify distinct pathways or describe novel interference principles, our findings provide important new insight in potential activities of triplet repeat AONs.

In a series of simple biochemical test tube experiments, we first investigated whether triplet repeat 2′-OMe/PT AONs might carry intrinsic endoribonuclease activity, similar to

ribozymes or DNAzymes.[23] In none of the experiments RNase activity was detected. Although we also tested several cell-free or protein-free conditions (data not shown), it cannot be excluded that the right cellular reaction conditions were not fully reproduced.

We provide evidence that PS260, a (CAG)7 gapmer, efficiently reached various (CUG)n RNA targets, irrespective of repeat length, and recruited endogenous RNase-H for a first endonucleolytic cleavage. We expect that unprotected 5′ and 3′ RNA segments will be degraded after initial cleavage by conventional exonucleases as part of the quality control system in the cell.[33] Surprisingly, PS260 showed only little selectivity between expanded and normal-sized *hDMPK* transcripts in patient cells, suggesting that either RNase-H activity took place in both the nucleus and the cytosol, or that degradation already occurred swiftly, during or shortly after RNA synthesis in the nucleus. Our observations contrast with a report that an LNA-based repeat gapmer did cleave *hDMPK (CUG)40*, but not *(CUG)12* transcripts;[10] and also with a study in which a (CAG)6 LNA gapmer did not reduce *CASK (CUG)16* RNA.[34] The reason for these discrepancies should probably be found in oligo chemistry, concentration or model system used.

Nucleotide analogs like morpholinos or modifications like 2′-OMe do not support RNase-H–dependent degradation. These AONs must therefore use distinct pathways, explaining why PS58, a 2′-OMe/PT (CAG)7 AON, and PS260, displayed differential (CUG)n length-dependent silencing.

The RNAi pathway is unlikely to be involved in activity of fully 2′-OMe/PT AONs or (CAG)n morpholinos. Imperfect hybrids of 2′-OMe/PT or morpholino (CAG)n AONs, or perfect hybrids that these AONs may form with (CUG)n transcripts, will not be recognized by the RNAi machinery.[35–37] Furthermore, the size of the shortest effective AON (15 nucleotides) and tolerated 5′ modifications like a fluorescent group (as in FAM-PS58) or a peptide (data not shown) render involvement of the RNAi pathway highly unlikely.[38,39] Also, we did not find evidence for AON-induced processing of expanded *hDMPK* transcripts into (CUG)n siRNAs that could trigger degradation of (CAG)n transcripts.

Fully 2′-OMe/PT-modified AONs, like PS58, and morpholinos are usually designed and employed to serve as blocking oligos to modulate splicing or prevent translation.[13,40] As discussed above, PS146, a 30 nucleotide long 2′-OMe/PT AON, exhibits splicing modulating activity. We could not detect a similar activity of (CAG)n AONs towards *hDMPK (CUG)500* transcripts. The most logical explanation for this observation is the location of the (CUG)n repeat in the final exon of the *hDMPK* gene. The only reported splice acceptor, located around 35 nucleotides 3′ of the (CUG)n tract, is only rarely used[22,41] and probably too weak to be amenable to manipulation.

A (AGC)8A morpholino reportedly blocked Mbnl1 protein binding to transgenic (CUG)250 transcripts in a mouse model for DM1-related RNA toxicity.[9] In that study, cytoplasmic levels of expanded transcripts raised upon treatment, but the total amount of (CUG)250 transcripts was ~50% reduced. A comparable reduction was reported for expanded Huntingtin (CAG)n RNA using a (GCT)6G LNA-type blocking oligonucleotide.[42] The molecular mechanism underlying the activity

of AGC morpholino is unknown, but it was suggested that the displacement of expanded transcripts to the cytoplasm may have induced *hDMPK* mRNA decay. We propose that a similar mechanism may be at play for our (CAG)n morpholino and the 2′-OMe/PT AONs examined here. Alternatively, this class of AONs may activate a yet to be identified RNase or RNA decay program in nucleus or cytoplasm. Our current working hypotheses are that the interaction between (CAG)n AONs and the (CUG)n repeat attracts proteins involved in RNA degradation or that AON binding displaces RNA-protecting proteins resulting in naked RNA, which is extremely sensitive to RNases. Further detailed studies into these interesting possibilities are warranted.

In sum, we provide further evidence that the expanded (CUG)n segment in *hDMPK* mRNA, being the product from the only known mutation in DM1, forms an attractive target for AON therapy. For development of future treatment modalities, chemical structure and oligo length in combination with the rather special sequence content needed—*i.e.,* the complementary (CAG)n repeat character—have now been identified as crucial determinants. By extrapolation of findings, our results also open up interesting possibilities for therapy of other triplet repeat diseases.

Materials and methods

Cell culture. Immortalized DM500 myoblasts were derived from DM300-328 mice[43] and cultured and differentiated to myotubes as described.[8] Human DM1 myoblast lines were derived and cultured as described.[18]

Oligonucleotides. AONs and siRNAs were complementary to the (CUG)n repeat. Their sequence and chemistry are listed in Figure 1a and **Supplementary Table S1**, except for control oligos scrambled-PS58: 5′-CAGAGGACCACC AGACCAAGG-3′; and PS57: 5′-CUGCUGCUGCUGCUGCU GCUG-3′ (both fully 2′-OMe/PT-modified). All AONs and siRNAs were provided by Prosensa (Leiden, The Netherlands), except morpholino PS304, which was purchased coupled to an octaguanidine dendrimer from Gene Tools (Philomath, OR) and control siRNA, purchased from Thermo Scientific Dharmacon (Lafayette, CO).

Oligotransfection. AONs were transfected using polyethyleneimine (ExGen 500; Fermentas, Glen Burnie, MD) according to the manufacturer's instructions. Typically, 5 µl polyethyleneimine/µg AON was added at a final AON concentration of 200 nmol/l in differentiation medium to myotubes on day 5 of myogenesis or in Opti-MEM (Invitrogen, Carlsbad, CA) to myoblasts. For concentration–response experiments, oligo concentrations between 0.01 and 500 nmol/l were applied. Four hours later, fresh medium was supplemented to a maximum volume of 2 ml medium/well. Medium was changed 20 hours later. RNA was isolated 48 hours after start of transfection.

PS304 was tested following the protocol above with the exception that no transfection reagent was used.

siRNAs were administered twice (on subsequent days: day 4 and 5 of myogenesis) using a Lipofectamine 2000-based transfection protocol (Invitrogen) according to the manufacturer's instructions, at a final concentration of 50 nmol/l. Four hours following addition of the transfection mix and 24 hours

after start of the second transfection, medium was changed. RNA was isolated 48 hours after the second transfection.

Oligo stability. AONs (7.5 pmol) were radioactively labeled by T4 polynucleotide kinase in the presence of $[\gamma\text{-}^{32}P]$-ATP and then purified on G50 columns followed by ethanol precipitation.

DM500 myoblast whole cell extract was prepared by scraping ~1×10^6 cells per well in phosphate-buffered saline (PBS) containing 1 mmol/l EDTA. Cells were collected *via* centrifugation (1,000 rpm, 5 minutes), packed cell volume was estimated and cells were resuspended in 1× packed cell volume of 10 mmol/l Tris-HCl; pH 8.0, 1.5 mmol/l $MgCl_2$, 10 mmol/l KCl, 1 mmol/l DTT and 1× Protease Inhibitory Cocktail (Roche, Almere, The Netherlands). Cell suspensions were placed on ice for 15 minutes and homogenized using a pestle. Whole cell lysate was collected after centrifugation (14,000*g*, 10 minutes).

AONs (~2 pmol) were incubated with 5 µl whole cell lysate at 37 °C for 0, 3 or 24 hours, reaction was stopped by adding 140 mmol/l sodium acetate; pH 5.0, phenol/$CHCl_3$ and water phase was collected (14,000*g*, 10 minutes, 4 °C). Oligo was precipitated by the addition of three volumes of ethanol. The oligo precipitate was washed with 70% (vol/vol) ethanol, air dried and dissolved in sample buffer (75% deionized formamide, 25% glycerol). Samples were loaded on a 12% (wt/vol) acrylamide/bisacrylamide (37.5:1) denaturing urea (8 mol/l) PAGE gel in 1× MOPS buffer. After running, gels were dried at 70 °C for 2 hours and exposed to X-ray film (X-Omat AR; Kodak, Rochester, NY).

RNA isolation. RNA was isolated using the Aurum Total RNA Mini Kit (Bio-Rad, Hercules, CA), according to the manufacturer's protocol.

Northern blotting. Northern blotting was done as described.[8] Random-primed ^{32}P-labeled human *DMPK* (2.6 kb cDNA), rat *Gapdh* (1.1 kb cDNA), and mouse *Mapkap1* (1.1 kb cDNA) probes were used. Signals were quantified by phospho-imager analysis (GS-505 or Molecular Imager FX; Bio-Rad) and analyzed with Quantity One (Bio-Rad) or ImageJ software. Gapdh levels were used for normalization. RNA levels of control samples were set at 100%.

RT-PCR. Primer sets for PCR were designed using Primer-BLAST[44] in the National Center for Biotechnology Information database and validated *in silico* using OligoAnalyzer 3.1[45] to prevent formation of hairpins and dimers during amplification. Resulting products were visualized on agarose gels and sequenced to verify identity and triplet repeat length. Primer sequences are listed in **Supplementary Table S2**.

For RT, typically 0.5 µg RNA was subjected to cDNA synthesis using the SuperScript first-strand synthesis system with random hexamer primers in a total volume of 20 µl. For RT-PCR experiments in presence of AONs, AONs were added to the RNA to reach the indicated final concentration and incubated for 15 minutes on ice before starting the RT reaction.

For semi-quantitative RT-PCR, 1 µl of cDNA preparation was used in a PCR according to standard procedures. In RT⁻ control experiments, reverse transcriptase was omitted. The signal for β-actin was used for normalization. Cycle number was 18 for β-actin and 22-31 for other primer sets. PCR products were analyzed on 1.5–2.5% agarose gels stained by ethidium bromide. Quantification of signals was done using Labworks 4.0 software (UVP BioImaging Systems, Cambridge, UK). Values for control samples were set at 100%.

For RT-qPCR, all procedures were performed following the Minimum Information for Publication of Quantitative Real-Time PCR Experiments (MIQE) guidelines.[46] Amplification efficiency of primer sets was determined using standard curves (serial dilutions; tenfold to 5,000-fold range). Primers sets displaying <90% efficiency in product amplification were ruled out and redesigned. cDNA preparations (see RT reaction above) were diluted 200–500-fold to avoid PCR inhibition by RT components; 3 µl of this dilution was mixed in a final volume of 10 µl containing 5 µl 2X Sybr Green mix (Roche Applied Science, Almere, The Netherlands) and 400 nmol/l of each primer using the CAS-1200 automated pipetting system (Corbett Life Science/ Qiagen, Venlo, The Netherlands). No template control and no reverse transcriptase control (RT⁻) were included in each qPCR run to detect possible contaminations. Samples were analyzed using the Rotor-Gene 6000 (Corbett Life Science) or CFX96 Real-time System (Bio-Rad). A melting curve was obtained for each sample to confirm single product amplification. Relative mRNA levels were calculated using the ΔΔCt method.[47] Both *Actb* and *Gapdh* were used for normalization. We validated that these reference genes were not affected by the treatment and had an optimal M stability value[48] under all experimental conditions. Values of control samples were set at 100%.

AON hybridization–ligation assay. PS58 concentrations were determined by a hybridization–ligation assay as published by Yu *et al.*[49] with a few modifications: Template DNA probe (5′-GAATAGACGCTGCTGCTGCTGCTGCTGCTG-biotin-3′) and ligation DNA probe (5′-P-CGTCTATTC-digoxigenin (DIG)-3′) were used. Samples were incubated with the template probe (50 nmol/l) at 37 °C for 1 hour and hybridized samples were transferred to streptavidin-coated plates. Subsequently, plates were washed four times and the DIG-labeled ligation probe (2 nmol/l) was added and incubated for 30 minutes at ambient temperature. DIG label was detected using an anti-DIG-POD (1:7,500; Roche Diagnostics, Almere, The Netherlands), visualized with a 3,3′,5,5′-tetramethylbenzidine substrate (Sigma Aldrich, Zwijndrecht, The Netherlands). The reaction was stopped using maleic acid (345 mmol/l; Sigma Aldrich). Absorption was measured at 450 nm using a BioTek Synergy HT plate reader (Beun de Ronde, Abcoude, The Netherlands). All samples and calibration curves were diluted (fit to criteria of the assay) in PBS. Absorption was read against a calibration curve of PS58 in PBS. A sample containing only PBS was used as correction for background.

Live cell imaging. DM500 myoblasts were cultured on gelatin-coated glass-bottom Willco dishes (Willco Wells, Amsterdam, The Netherlands). Cells were analyzed directly after addition of the transfection mix containing FAM-PS58 or Cy3-PS138 in RPMI medium without phenol red and including 10 mmol/l HEPES and 10% fetal calf serum (Invitrogen). A Zeiss LSM510 meta confocal laser-scanning microscope was used, equipped with a temperature controlled CO_2 incubator

(type S) and sample stage. For recording of oligo uptake, we used a PlanApochromatic 63×, 1.4 NA oil immersion DIC lens (Carl Zeiss, Jena, Germany).

Western blotting. DM1 patient 21/200 myoblasts or DM500 mouse myotubes were transfected with PS147, PS58, PS146, PS260 or PS261 as indicated (200 nmol/l) or mock transfected and 72 hours later lysed in lysis buffer (TBS, 1% Nonidet P-40, 1 mmol/l PMSF, and Protease Inhibitory Mixture (Roche)) on ice. Cleared lysates were separated on an 8% SDS/PAGE gel and transferred to PVDF (Amersham Pharmacia Biotech, Piscataway, NJ). Blots were incubated with DMPK-specific antibody B79[21] or anti-SIN1/Mapkap1 antibody (ab71152; Abcam, Cambridge, UK) and β-tubulin monoclonal antibody E7 (Developmental Studies Hybridoma Bank, University of Iowa, Iowa City, IA), followed by electrochemiluminescence detection. Quantification of signals was done using ImageJ software. Values for mock-treated samples were set at 100%.

Experiments using in vitro-transcribed triplet repeat RNA. (CUG)n and (CAG)n RNA was generated by *in vitro* transcription of a *hDMPK* (CTG)90 DNA template carrying flanking T7 and SP6 promoters. The *hDMPK* (CTG)90 template was generated by PCR using a *hDMPK* cDNA construct bearing a (CTG)90 repeat,[50] T7-*hDMPK* forward primer: 5′-GAATTTAATACGACTCACTATAGGGAGAACGGGGCTC-GAAGGGT-3′ and SP6-*hDMPK* reverse primer: 5′-ATTTAG-GTGACACTATAGAAGGGCGTCATGCACAAGAAA-3′ and sequenced to verify triplet repeat number. (CUG)90 and (CAG)90 RNAs were synthesized in presence of [α-32P]GTP, using the MEGAscript *in vitro* transcription kit (Applied Biosystems/Ambion, Austin, TX) according to the manufacturer's protocol.

To confirm AON binding to expanded triplet repeat RNA, (CUG)90 RNA was incubated with a concentration series (1, 10, and 100 μmol/l) of PS58 in 50 mmol/l Tris-HCl; pH 7.5 and 25 mmol/l $MgCl_2$ for 2 hours at 37 °C. Sample buffer was added to a final concentration of 50% deionized formamide and 30% glycerol and samples were run at room temperature on a denaturing polyacrylamide gel (5% acryl/bisacryl, 8 mol/l urea) in 1× MOPS. Gels were dried and exposed to X-ray film (X-Omat AR; Kodak).

To reveal binding specificity, (CUG)90 and (CAG)90 RNAs were incubated with 100 μmol/l AONs in the presence of 50 mmol/l Tris-HCl; pH 7.5, 50 mmol/l NaCl, 25 mmol/l $MgCl_2$, and 1 mmol/l EDTA for 2 hours at 37 °C. Samples were next analyzed by electrophoresis as described above.

To examine RNase-H–dependent activity, (CUG)n RNA was dissolved in 50 mmol/l Tris-HCl; pH 7.5, 50 mmol/l KCl, 5 mmol/l $MgCl_2$, and 1 mmol/l DTT and incubated with 60–100 μmol/l AON in the presence of 20 U/ml RNase-H for 1 hour at 37 °C. Samples were analyzed by electrophoresis as described above with the exception that the 1× MOPS running buffer was heated to 70 °C before start of electrophoresis to induce dissociation between AONs and (CUG)n RNA.

To examine intrinsic oligo catalytic activity, (CUG)n RNA was dissolved in 100 mmol/l Tris-HCl; pH 7.5, 100 mmol/l NaCl, and 1 mmol/l EDTA and incubated with 100 μmol/l AON for 2 hours at 37 °C in the presence of 3.5 or 25 mmol/l $MgCl_2$. Samples were analyzed by electrophoresis as described above.

Complement activation assay. The potency of AONs to activate the complement pathway was demonstrated using Li+ heparin plasma from cynomolgus monkeys (kindly provided by CIT, France) and Li+ heparin plasma from healthy human donors (Sanquin, Amsterdam, The Netherlands). AONs were added to plasma in various concentrations (25, 50, 150, and 300 μg/ml in a dilution of ~1:20 (volume AON/volume plasma)) and the samples were incubated at 37 °C for 30 minutes. The reaction was terminated by putting the samples on ice and adding ice-cold diluents according to the manufacturer's protocol (Quidel, San Diego, CA). Bb and C3a concentrations were determined by ELISA (Quidel). First generation oligonucleotide PS455 (ISIS 5132) was included as a positive control, as this oligo has been shown to activate the complement pathway.[25]

Statistical analysis. Northern blot and PCR signals were analyzed using an unpaired Student's *t*-test or a one-way analysis of variance. All values in graphs are presented as the mean ± SEM. Pearson's correlation was applied to evaluate whether a correlation exists between silencing efficacy and number of CTG triplets in *hDMPK* alleles in human myoblasts. Differences between groups were considered significant when $P < 0.05$: *$P < 0.05$; **$P < 0.01$; ***$P < 0.001$. Statistical analyses and sigmoidal concentration curve fitting were performed with Graph-Pad Prism 4 software (GraphPad Software, La Jolla, CA).

Supplementary material
Figure S1. AON stability in cell extract.
Figure S2. Concentration–response curve of PS142 including raw data.
Figure S3. Differential uptake and localization of AONs in DM500 myoblasts.
Figure S4. Schematic representation of triplet repeat transcripts and segments thereof, analyzed by RT-(q)PCR.
Figure S5. Expression of mouse transcripts, carrying a small (CUG)n repeat, after transfecting DM500 myotubes with a selection of AONs.
Figure S6. Control experiments to exclude perturbing effects of AONs during RT-(q)PCR quantification.
Figure S7. (CAG)n oligos can modulate alternative splicing of the (CUG)n-containing exon in the *MAP3K4* primary transcript.
Figure S8. Test tube experiments using *in vitro*-synthesized RNA bearing a (CUG)90 or (CAG)90 tract.
Figure S9. Complement activation assay.
Table S1. siRNAs (RNA duplexes) used in this study.
Table S2. PCR primers used in this study (5′ -> 3′).

cell model and to Denis Furling (Institut de Myologie, Paris, France) for providing human DM1 myoblast lines. We thank Makoto Koizumi (Sankyo Co., Ltd., Tokyo, Japan) for providing ethylene-bridged nucleic acid nucleosides as building blocks for the synthesis of ethylene-bridged nucleic acid-modified oligonucleotides. Data described in this paper are the subject of a patent application (inventors D.G.W. *et al.*). A.G.-B., S.A.M.M., J.van de G., S.B., and J.C.T.van D. report being employed by or having an equity interest in Prosensa Therapeutics B.V. The other authors declared no conflict of interest.

1. Groenen, P and Wieringa, B (1998). Expanding complexity in myotonic dystrophy. *Bioessays* **20**: 901–912.
2. Wheeler, TM and Thornton, CA (2007). Myotonic dystrophy: RNA-mediated muscle disease. *Curr Opin Neurol* **20**: 572–576.
3. Harper, PS (2001). Myotonic Dystrophy. WB Saunders: London, UK.
4. Zerylnick, C, Torroni, A, Sherman, SL and Warren, ST (1995). Normal variation at the myotonic dystrophy locus in global human populations. *Am J Hum Genet* **56**: 123–130.
5. Rau, F, Freyermuth, F, Fugier, C, Villemin, JP, Fischer, MC, Jost, B et al. (2011). Misregulation of miR-1 processing is associated with heart defects in myotonic dystrophy. *Nat Struct Mol Biol* **18**: 840–845.
6. Mahadevan, MS, Yadava, RS, Yu, Q, Balijepalli, S, Frenzel-McCardell, CD, Bourne, TD et al. (2006). Reversible model of RNA toxicity and cardiac conduction defects in myotonic dystrophy. *Nat Genet* **38**: 1066–1070.
7. Mulders, SA, van Engelen, BG, Wieringa, B and Wansink, DG (2010). Molecular therapy in myotonic dystrophy: focus on RNA gain-of-function. *Hum Mol Genet* **19**(R1): R90–R97.
8. Mulders, SA, van den Broek, WJ, Wheeler, TM, Croes, HJ, van Kuik-Romeijn, P, de Kimpe, SJ et al. (2009). Triplet-repeat oligonucleotide-mediated reversal of RNA toxicity in myotonic dystrophy. *Proc Natl Acad Sci USA* **106**: 13915–13920.
9. Wheeler, TM, Sobczak, K, Lueck, JD, Osborne, RJ, Lin, X, Dirksen, RT et al. (2009). Reversal of RNA dominance by displacement of protein sequestered on triplet repeat RNA. *Science* **325**: 336–339.
10. Lee, JE, Bennett, CF and Cooper, TA (2012). RNase H-mediated degradation of toxic RNA in myotonic dystrophy type 1. *Proc Natl Acad Sci USA* **109**: 4221–4226.
11. François, V, Klein, AF, Beley, C, Jollet, A, Lemercier, C, Garcia, L et al. (2011). Selective silencing of mutated mRNAs in DM1 by using modified hU7-snRNAs. *Nat Struct Mol Biol* **18**: 85–87.
12. Tashiro, F and Ueno, Y (1978). Ribonuclease H from rat liver. I. Partial purification and characterization of nuclear ribonuclease H1. *J Biochem* **84**: 385–393.
13. Kurreck, J (2003). Antisense technologies. Improvement through novel chemical modifications. *Eur J Biochem* **270**: 1628–1644.
14. Eisen, JS and Smith, JC (2008). Controlling morpholino experiments: don't stop making antisense. *Development* **135**: 1735–1743.
15. Morita, K, Hasegawa, C, Kaneko, M, Tsutsumi, S, Sone, J, Ishikawa, T et al. (2002). 2'-O,4'-C-ethylene-bridged nucleic acids (ENA): highly nuclease-resistant and thermodynamically stable oligonucleotides for antisense drug. *Bioorg Med Chem Lett* **12**: 73–76.
16. Krol, J, Fiszer, A, Mykowska, A, Sobczak, K, de Mezer, M and Krzyzosiak, WJ (2007). Ribonuclease dicer cleaves triplet repeat hairpins into shorter repeats that silence specific targets. *Mol Cell* **25**: 575–586.
17. Schroder, W, Cloonan, N, Bushell, G and Sculley, T (2004). Alternative polyadenylation and splicing of mRNAs transcribed from the human Sin1 gene. *Gene* **339**: 17–23.
18. Furling, D, Lemieux, D, Taneja, K and Puymirat, J (2001). Decreased levels of myotonic dystrophy protein kinase (DMPK) and delayed differentiation in human myotonic dystrophy myoblasts. *Neuromuscul Disord* **11**: 728–735.
19. Kozlowski, P, de Mezer, M and Krzyzosiak, WJ (2010). Trinucleotide repeats in human genome and exome. *Nucleic Acids Res* **38**: 4027–4039.
20. Gerwins, P, Blank, JL and Johnson, GL (1997). Cloning of a novel mitogen-activated protein kinase kinase kinase, MEKK4, that selectively regulates the c-Jun amino terminal kinase pathway. *J Biol Chem* **272**: 8288–8295.
21. Groenen, PJ, Wansink, DG, Coerwinkel, M, van den Broek, W, Jansen, G and Wieringa, B (2000). Constitutive and regulated modes of splicing produce six major myotonic dystrophy protein kinase (DMPK) isoforms with distinct properties. *Hum Mol Genet* **9**: 605–616.
22. Tiscornia, G and Mahadevan, MS (2000). Myotonic dystrophy: the role of the CUG triplet repeats in splicing of a novel DMPK exon and altered cytoplasmic DMPK mRNA isoform ratios. *Mol Cell* **5**: 959–967.
23. Bhindi, R, Fahmy, RG, Lowe, HC, Chesterman, CN, Dass, CR, Cairns, MJ et al. (2007). Brothers in arms: DNA enzymes, short interfering RNA, and the emerging wave of small-molecule nucleic acid-based gene-silencing strategies. *Am J Pathol* **171**: 1079–1088.
24. Henry, SP, Giclas, PC, Leeds, J, Pangburn, M, Auletta, C, Levin, AA et al. (1997). Activation of the alternative pathway of complement by a phosphorothioate oligonucleotide: potential mechanism of action. *J Pharmacol Exp Ther* **281**: 810–816.
25. Rudin, CM, Holmlund, J, Fleming, GF, Mani, S, Stadler, WM, Schumm, P et al. (2001). Phase I Trial of ISIS 5132, an antisense oligonucleotide inhibitor of c-raf-1, administered by 24-hour weekly infusion to patients with advanced cancer. *Clin Cancer Res* **7**: 1214–1220.
26. Mooers, BH, Logue, JS and Berglund, JA (2005). The structural basis of myotonic dystrophy from the crystal structure of CUG repeats. *Proc Natl Acad Sci USA* **102**: 16626–16631.
27. Koizumi, M (2006). ENA oligonucleotides as therapeutics. *Curr Opin Mol Ther* **8**: 144–149.
28. Robb, GB, Brown, KM, Khurana, J and Rana, TM (2005). Specific and potent RNAi in the nucleus of human cells. *Nat Struct Mol Biol* **12**: 133–137.
29. Sobczak, K, Wheeler, TM, Wang, W and Thornton, CA (2013). RNA interference targeting CUG repeats in a mouse model of myotonic dystrophy. *Mol Ther* **21**: 380–387.
30. Wansink, DG and Wieringa, B (2003). Transgenic mouse models for myotonic dystrophy type 1 (DM1). *Cytogenet Genome Res* **100**: 230–242.
31. Smith, PJ, Zhang, C, Wang, J, Chew, SL, Zhang, MQ and Krainer, AR (2006). An increased specificity score matrix for the prediction of SF2/ASF-specific exonic splicing enhancers. *Hum Mol Genet* **15**: 2490–2508.
32. Fiszer, A, Olejniczak, M, Switonski, PM, Wroblewska, JP, Wisniewska-Kruk, J, Mykowska, A et al. (2012). An evaluation of oligonucleotide-based therapeutic strategies for polyQ diseases. *BMC Mol Biol* **13**: 6.
33. Doma, MK and Parker, R (2007). RNA quality control in eukaryotes. *Cell* **131**: 660–668.
34. Nakamori, M, Gourdon, G and Thornton, CA (2011). Stabilization of expanded (CTG)•(CAG) repeats by antisense oligonucleotides. *Mol Ther* **19**: 2222–2227.
35. Chiu, YL and Rana, TM (2003). siRNA function in RNAi: a chemical modification analysis. *RNA* **9**: 1034–1048.
36. Amarzguioui, M, Holen, T, Babaie, E and Prydz, H (2003). Tolerance for mutations and chemical modifications in a siRNA. *Nucleic Acids Res* **31**: 589–595.
37. Braasch, DA, Jensen, S, Liu, Y, Kaur, K, Arar, K, White, MA et al. (2003). RNA interference in mammalian cells by chemically-modified RNA. *Biochemistry* **42**: 7967–7975.
38. Sun, X, Rogoff, HA and Li, CJ (2008). Asymmetric RNA duplexes mediate RNA interference in mammalian cells. *Nat Biotechnol* **26**: 1379–1382.
39. Chu, CY and Rana, TM (2008). Potent RNAi by short RNA triggers. *RNA* **14**: 1714–1719.
40. Summerton, JE (2007). Morpholino, siRNA, and S-DNA compared: impact of structure and mechanism of action on off-target effects and sequence specificity. *Curr Top Med Chem* **7**: 651–660.
41. Wansink, DG, van Herpen, RE, Coerwinkel-Driessen, MM, Groenen, PJ, Hemmings, BA and Wieringa, B (2003). Alternative splicing controls myotonic dystrophy protein kinase structure, enzymatic activity, and subcellular localization. *Mol Cell Biol* **23**: 5489–5501.
42. Hu, J, Matsui, M, Gagnon, KT, Schwartz, JC, Gabillet, S, Arar, K et al. (2009). Allele-specific silencing of mutant huntingtin and ataxin-3 genes by targeting expanded CAG repeats in mRNAs. *Nat Biotechnol* **27**: 478–484.
43. Seznec, H, Lia-Baldini, AS, Duros, C, Fouquet, C, Lacroix, C, Hofmann-Radvanyi, H et al. (2000). Transgenic mice carrying large human genomic sequences with expanded CTG repeat mimic closely the DM CTG repeat intergenerational and somatic instability. *Hum Mol Genet* **9**: 1185–1194.
44. Ye, J, Coulouris, G, Zaretskaya, I, Cutcutache, I, Rozen, S and Madden, TL (2012). Primer-BLAST: a tool to design target-specific primers for polymerase chain reaction. *BMC Bioinformatics* **13**: 134.
45. Owczarzy, R, Tataurov, AV, Wu, Y, Manthey, JA, McQuisten, KA, Almabrazi, HG et al. (2008). IDT SciTools: a suite for analysis and design of nucleic acid oligomers. *Nucleic Acids Res* **36**(Web Server issue): W163–W169.
46. Bustin, SA, Benes, V, Garson, JA, Hellemans, J, Huggett, J, Kubista, M et al. (2009). The MIQE guidelines: minimum information for publication of quantitative real-time PCR experiments. *Clin Chem* **55**: 611–622.
47. Livak, KJ and Schmittgen, TD (2001). Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. *Methods* **25**: 402–408.
48. Vandesompele, J, De Preter, K, Pattyn, F, Poppe, B, Van Roy, N, De Paepe, A et al. (2002). Accurate normalization of real-time quantitative RT-PCR data by geometric averaging of multiple internal control genes. *Genome Biol* **3**: RESEARCH0034.
49. Yu, RZ, Baker, B, Chappell, A, Geary, RS, Cheung, E and Levin, AA (2002). Development of an ultrasensitive noncompetitive hybridization-ligation enzyme-linked immunosorbent assay for the determination of phosphorothioate oligodeoxynucleotide in plasma. *Anal Biochem* **304**: 19–25.
50. van den Broek, WJ, Nelen, MR, Wansink, DG, Coerwinkel, MM, te Riele, H, Groenen, PJ et al. (2002). Somatic expansion behaviour of the (CTG)n repeat in myotonic dystrophy knock-in mice is differentially affected by Msh3 and Msh6 mismatch-repair proteins. *Hum Mol Genet* **11**: 191–198.

Supplementary Information accompanies this paper on the Molecular Therapy–Nucleic Acids website (http://www.nature.com/mtna)